Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

被引：39
作者：
van der Kooij, M. K. [1 ]
Joosse, A. [1 ]
Speetjens, F. M. [1 ]
Hospers, G. A. P. [2 ]
Bisschop, C. [2 ]
de Groot, J. W. B. [3 ]
Koornstra, R. [4 ]
Blank, C. U. [5 ]
Kapiteijn, E. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Clin Oncol, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands
[3] Isala, Dept Med Oncol, Zwolle, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[5] Netherlands Canc Inst NKI AVL, Dept Med Oncol, Amsterdam, Netherlands
来源：
ACTA ONCOLOGICA | 2017年 / 56卷 / 01期
关键词：
IPILIMUMAB; TRIAL;
D O I：
10.1080/0284186X.2016.1260773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：101 / 103
页数：3
相关论文
共 50 条
  • [31] Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes
    Xu, Lucy T.
    Funchain, Pauline F.
    Bena, James F.
    Li, Manshi
    Tarhini, Ahmad
    Berber, Eren
    Singh, Arun D.
    OCULAR ONCOLOGY AND PATHOLOGY, 2019, 5 (05) : 323 - 332
  • [32] Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
    Seremet, Teofila
    Jansen, Yanina
    Planken, Simon
    Njimi, Hassan
    Delaunoy, Melanie
    El Housni, Hakim
    Awada, Gil
    Schwarze, Julia Katharina
    Keyaerts, Marleen
    Everaert, Hendrik
    Lienard, Danielle
    Del Marmol, Veronique
    Heimann, Pierre
    Neyns, Bart
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
  • [33] Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma
    Wang, Zhijian
    Xie, Yuhao
    Wang, Jing-Quan
    Cheng, Yuanhui
    Fleishman, Joshua
    Chen, Zhe-Sheng
    Chen, Yun
    DRUGS OF TODAY, 2023, 59 (03) : 179 - 193
  • [34] Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions
    Shui, Irene M.
    Scherrer, Emilie
    Frederickson, Andrew
    Li, Joyce W.
    Mynzhassarova, Anel
    Druyts, Eric
    Tawbi, Hussein
    MELANOMA RESEARCH, 2022, 32 (06) : 393 - 404
  • [35] Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma
    Lee, Jenny H. J.
    Lyle, Megan
    Menzies, Alexander M.
    Chan, Matthew M. K.
    Lo, Serigne
    Clements, Arthur
    Carlino, Matteo S.
    Kefford, Richard F.
    Long, Georgina, V
    PIGMENT CELL & MELANOMA RESEARCH, 2018, 31 (03) : 404 - 410
  • [36] Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment
    Cheng, Jiaxing
    2020 INTERNATIONAL CONFERENCE ON ENERGY, ENVIRONMENT AND BIOENGINEERING (ICEEB 2020), 2020, 185
  • [37] Safety and efficacy of anti-PD1 therapy for metastatic melanoma and non-small cell lung cancer in patients with concurrent viral hepatitis
    Kothapalli, A.
    Khattak, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 79 - 79
  • [38] Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
    Klee, Gina
    Kurzhals, Jonas
    Hagelstein, Victoria
    Zillikens, Detlef
    Recke, Andreas
    Langan, Ewan A.
    Terheyden, Patrick
    MELANOMA RESEARCH, 2021, 31 (05) : 464 - 471
  • [39] Potential of New Therapies like Anti-PD1 in Kidney Cancer
    Gunturi, Anasuya
    McDermott, David F.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (01) : 137 - 146
  • [40] Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
    Howlett, Sarah
    Carter, Thomas J.
    Shaw, Heather M.
    Nathan, Paul D.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
12345